Read our 2025 full year results
Results and presentations

A diversified portfolio across clinical stages

Commercial companies
Commercial companies
Late-stage clinical companies
Late-stage clinical companies
Clinical companies
Clinical companies
Pre-clinical companies
Pre-clinical companies
Explore our portfolio

Making a positive contribution

We are committed to managing our business in a sustainable way, investing responsibly, and supporting our portfolio companies in making positive contributions to society by developing treatments that will make a difference to the lives of patients and their families.

Sustainability

Latest news

Northern Gritstone invests in Manchester spinout Apini

Quell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease

Beacon Therapeutics Strengthens Leadership Team with the Appointment of Dr. Daniel Chung as Chief Medical Officer

Spur Therapeutics Presents Positive New Preclinical Data on Its Gene Therapy Candidate for GBA1 Parkinson’s Disease at 2025 GBA1 Meeting

iOnctura bolsters leadership team with new appointments

Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for FLT201, its Clinical-Stage Gene Therapy Candidate in Gaucher Disease

Slingshot Therapeutics strengthens its team through the appointment of Ed Savory as Head of Chemistry

Resolution Therapeutics Announces Regenerative Macrophage Therapy (RMT) Manufacturing Process & Candidate Testing Suite at ASGCT 2025

Kesmalea Therapeutics Appoints Industry Veteran Tim Clackson to Board of Directors

iOnctura commences randomised Phase I/II study in non-small cell lung cancer

Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025

Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation

Autolus Therapeutics Announces License of AUCATZYL®

iOnctura commences randomized Phase II study in metastatic uveal melanoma

Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer

OMass Therapeutics appoints Birgitte Volck as Non-Executive Director

Third Quarter Results FY2025

Spur Therapeutics Announces Positive Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Gene Therapy Candidate for Gaucher Disease, at WORLDSymposium™

View all news
2024 Annual Report front cover

2024 Annual Report

Our Annual Report and Accounts 2024 provides an overview of our most recent financial year, as we continue to execute our clear strategy for growth and patient impact.

03.07.24 | pdf (4.55Mb)
Download

An expert multi-disciplinary team, attracting world-class talent

We are differentiated by our people, who identify innovative technology and take a commercial approach to building businesses capable of delivering transformational treatments to patients.

Our people

Search